Donepezil

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Stroke

Conditions

Stroke, Aphasia

Trial Timeline

Feb 1, 2003 → Mar 1, 2005

About Donepezil

Donepezil is a approved stage product being developed by Pfizer for Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT00196690. Target conditions include Stroke, Aphasia.

What happened to similar drugs?

6 of 20 similar drugs in Stroke were approved

Approved (6) Terminated (6) Active (10)
🔄SPT-07A injectionSinopharmPhase 3
StatinShionogiApproved
AlteplaseKyowa KirinApproved
AbciximabEli LillyPhase 3
AbciximabEli LillyPhase 3
🔄Ticagrelor + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00174382Phase 3Terminated
NCT00182845ApprovedCompleted
NCT00196690ApprovedCompleted

Competing Products

20 competing products in Stroke

See all competitors
ProductCompanyStageHype Score
SPT-07A injectionSinopharmPhase 3
36
Osmotic drugsSinopharmPre-clinical
33
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
SUN13837 + placeboDaiichi SankyoPhase 2
27
DS-1040b + AspirinDaiichi SankyoPhase 1
29
piclozotan low dose + placebo + piclozotan high doseDaiichi SankyoPhase 2
27
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxabanDaiichi SankyoPhase 3
40
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
ASP2246Astellas PharmaPhase 1/2
39
Neu2000KWL + Neu2000KWL + Neu2000KWL + PlacebosSun PharmaceuticalPhase 2
35
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
AlteplaseKyowa KirinApproved
43
ONO-2506 + ONO-2506 + ONO-2506Ono PharmaceuticalPhase 2/3
38
AbciximabEli LillyPhase 3
32
AbciximabEli LillyPhase 3
32